Therapeutic Uses of HSP90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC)

Title:Therapeutic Uses of HSP90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC)

Volume: 19 Issue: 4

Author(s): Anam Akram, Sara Khalil, Sobia Ahsan Halim*, Hooria Younas, Sadaf Iqbal and Saima Mehar

Affiliation:

• Department of Biochemistry, Kinnaird College for Women, Lahore-54000,Pakistan

Keywords: Heat shock protein 90, non-small-cell lung carcinoma, inhibitors, drugs, clinical trials, co-chaperons, mutations.

Abstract: Background: Non-Small Cell Lung Carcinoma is one of the major cause of morbidity and mortality worldwide with an incidence rate of 1.3 million cases per year. Heat shock protein 90 (HSP90) is a promising drug target in cancer treatment. HSP90 is required to activate numerous eukaryotic proto-oncogenic protein kinases, hence play a prominent role in cancer.

Method: We reviewed fifty-five articles to highlight the importance of HSP90 in NSCLC and the recent developments of its inhibitors.

Results: This review showed that HSP90 inhibitors i.e. Ganestespib have shown great potential in the treatment of non-small cell lung carcinoma (NSCLC). Different HSP90 inhibitors has been designed till date that acts as effective drugs in tumour suppression. However, the utility of these drugs has been limited due to several drawbacks including hepato-toxicity, poor solubility, and poorly tolerated formulations.

Conclusion: The goal of this review is to present the data in support of use of HSP90 inhibitors in NSCLC and to provide an overview of the on-going clinical trials involving new-generation HSP90 inhibitors.

Cite this article as:

Akram Anam , Khalil Sara, Halim Ahsan Sobia *, Younas Hooria , Iqbal Sadaf and Mehar Saima , Therapeutic Uses of HSP90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC), Current Drug Metabolism 2018; 19 (4) . https://dx.doi.org/10.2174/1389200219666180307122441